Show simple item record

dc.contributor.authorBlass, Keith
dc.date.accessioned2009-05-18T18:22:56Z
dc.date.available2009-05-18T18:22:56Z
dc.date.issued2009-01-28
dc.identifier.urihttps://hdl.handle.net/1813/12734
dc.description.abstractCanine immune-mediated thrombocytopenia (IMT) is a potentially fatal disease mediated by platelet-bound antibodies that initiate destruction of platelets by the mononuclear phagocytic system. IMT may be classified as a primary condition, for which there is no apparent inciting cause for platelet destruction, or as a secondary condition, in which a primary disease process precipitates immune-mediated platelet destruction. Diagnosis of primary IMT is made by documentation of severe thrombocytopenia in the absence of an obvious infectious or neoplastic process, and response to immunosuppressive therapy. Traditionally, treatment has consisted of the administration of glucocorticoids, with or without co-administration of additional immunosuppressive drugs, most commonly azathioprine. Use of other immunosuppressive treatments, among them vincristine and human immunoglobulin G, have also been reported. The use of mycophenolate mofetil as an adjunct treatment has not been reported. Administration of platelet transfusions for IMT is controversial, as transfused platelets have a short survival time and questionable functionality.en_US
dc.language.isoen_USen_US
dc.relation.ispartofseriesSenior seminar paperen_US
dc.relation.ispartofseriesSeminar SF610.1 2009 B54en_US
dc.subjectDogs -- Diseases -- Case studiesen_US
dc.titlePrimary immune-mediated thrombocytopenia in a Shih-Tzuen_US
dc.typeterm paperen_US


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Statistics